{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-044286","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.402259+00:00","generated_at":"2026-05-21T06:49:03.554418+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M","bullets":["Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.","Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.","Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.","Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-044286","json":"https://secwatch.observer/filing/0001213900-25-044286.json","markdown":"https://secwatch.observer/filing/0001213900-25-044286.md","text":"https://secwatch.observer/filing/0001213900-25-044286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/0001213900-25-044286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390025044286/ea0242203-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:49:03.554418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}